3.21 (-%)
As of Nov 01, 2024
Source:
We are a clinical-stage, biotechnology company, developing new treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer (mCRC), pancreatic cancer, metastatic castrate-resistant prostate cancer (mCRPC) and leukemias. By integrating biomarkers into our clinical development programs, we will be able to identify patients who are most likely to respond to treatment across a number of cancer types and associated indications
Country | United States |
Headquarters | san diego, california |
Phone Number | 858-952-7570 |
Industry | manufacturing |
CEO | Mark Erlander |
Website | www.clinicialtrials.gov |